|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brock A, Krause S and Ingber DE: Control
of cancer formation by intrinsic genetic noise and
microenvironmental cues. Nat Rev Cancer. 15:499–509. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Joyce JA and Pollard JW:
Microenvironmental regulation of metastasis. Nat Rev Cancer.
9:239–252. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jia Q, Dong Q and Qin L: CCN: Core
regulatory proteins in the microenvironment that affect the
metastasis of hepatocellular carcinoma? Oncotarget. 7:1203–1214.
2016.
|
|
5
|
Chang CC, Lin BR, Wu TS, Jeng YM and Kuo
ML: Input of microenvironmental regulation on colorectal cancer:
Role of the CCN family. World J Gastroenterol. 20:6826–6831. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Riser BL, Barnes JL and Varani J: Balanced
regulation of the CCN family of matricellular proteins: A novel
approach to the prevention and treatment of fibrosis and cancer. J
Cell Commun Signal. 9:327–339. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Perbal B: CCN proteins: A centralized
communication network. J Cell Commun Signal. 7:169–177. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Joliot A, Triller A, Volovitch M and
Prochiantz A: Are embryonic forms of NCAM homeobox receptors? C R
Acad Sci III. 314(Suppl 9): S59–S63. 1992.In French.
|
|
9
|
Kyurkchiev S, Yeger H, Bleau AM and Perbal
B: Potential cellular conformations of the CCN3 (NOV) protein. Cell
Commun Signal. 2:92004. View Article : Google Scholar
|
|
10
|
Desnoyers L: Structural basis and
therapeutic implication of the interaction of CCN proteins with
glycoconjugates. Curr Pharm Des. 10:3913–3928. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gery S, Xie D, Yin D, Gabra H, Miller C,
Wang H, Scott D, Yi WS, Popoviciu ML, Said JW, et al: Ovarian
carcinomas: CCN genes are aberrantly expressed and CCN1 promotes
proliferation of these cells. Clin Cancer Res. 11:7243–7254. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lv H, Fan E, Sun S, Ma X, Zhang X, Han DM
and Cong YS: Cyr61 is up-regulated in prostate cancer and
associated with the p53 gene status. J Cell Biochem. 106:738–744.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsai MS, Hornby AE, Lakins J and Lupu R:
Expression and function of CYR61, an angiogenic factor, in breast
cancer cell lines and tumor biopsies. Cancer Res. 60:5603–5607.
2000.PubMed/NCBI
|
|
14
|
Ladwa R, Pringle H, Kumar R and West K:
Expression of CTGF and Cyr61 in colorectal cancer. J Clin Pathol.
64:58–64. 2011. View Article : Google Scholar
|
|
15
|
Jiang WG, Watkins G, Fodstad O,
Douglas-Jones A, Mokbel K and Mansel RE: Differential expression of
the CCN family members Cyr61, CTGF and Nov in human breast cancer.
Endocr Relat Cancer. 11:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin BR, Chang CC, Chen RJ, Jeng YM, Liang
JT, Lee PH, Chang KJ and Kuo ML: Connective tissue growth factor
acts as a therapeutic agent and predictor for peritoneal
carcinomatosis of colorectal cancer. Clin Cancer Res. 17:3077–3088.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng YZ, Chen PP, Wang Y, Yin D, Koeffler
HP, Li B, Tong XJ and Xie D: Connective tissue growth factor is
overexpressed in esophageal squamous cell carcinoma and promotes
tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J
Biol Chem. 282:36571–36581. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bennewith KL, Huang X, Ham CM, Graves EE,
Erler JT, Kambham N, Feazell J, Yang GP, Koong A and Giaccia AJ:
The role of tumor cell-derived connective tissue growth factor
(CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 69:775–784.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maillard M, Cadot B and Ball RY, Maillard
M, Cadot B and Ball RY: Differential expression of the ccn3 (nov)
proto-oncogene in human prostate cell lines and tissues. Mol
Pathol. 54:275–280. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang T, Zhao C, Luo L, Xiang J, Sun Q,
Cheng J and Chen D: The clinical and prognostic significance of
CCN3 expression in patients with cervical cancer. Adv Clin Exp Med.
22:839–845. 2013.
|
|
21
|
Chen PP, Li WJ, Wang Y, Zhao S, Li DY,
Feng LY, Shi XL, Koeffler HP, Tong XJ and Xie D: Expression of
Cyr61, CTGF, and WISP-1 correlates with clinical features of lung
cancer. PLoS One. 2:e5342007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chien W, Kumagai T, Miller CW, Desmond JC,
Frank JM, Said JW and Koeffler HP: Cyr61 suppresses growth of human
endometrial cancer cells. J Biol Chem. 279:53087–53096. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maeta N, Osaki M, Shomori K, Inaba A,
Kidani K, Ikeguchi M and Ito H: CYR61 downregulation correlates
with tumor progression by promoting MMP-7 expression in human
gastric carcinoma. Oncology. 73:118–126. 2007. View Article : Google Scholar
|
|
24
|
Chien W, Yin D, Gui D, Mori A, Frank JM,
Said J, Kusuanco D, Marchevsky A, McKenna R and Koeffler HP:
Suppression of cell proliferation and signaling transduction by
connective tissue growth factor in non-small cell lung cancer
cells. Mol Cancer Res. 4:591–598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bleau AM, Planque N, Lazar N, Zambelli D,
Ori A, Quan T, Fisher G, Scotlandi K and Perbal B:
Antiproliferative activity of CCN3: Involvement of the C-terminal
module and post-translational regulation. J Cell Biochem.
101:1475–1491. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thibout H, Martinerie C, Créminon C,
Godeau F, Boudou P, Le Bouc Y and Laurent M: Characterization of
human NOV in biological fluids: An enzyme immunoassay for the
quantification of human NOV in sera from patients with diseases of
the adrenal gland and of the nervous system. J Clin Endocrinol
Metab. 88:327–336. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tanaka S and Sugimachi K, Saeki H,
Kinoshita J, Ohga T, Shimada M, Maehara Y and Sugimachi K: A novel
variant of WISP1 lacking a Von Mayebrand type C module
overexpressed in scirrhous gastric carcinoma. Oncogene.
20:5525–5532. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tanaka S, Sugimachi K, Maehara S, Shimada
M and Maehara Y: A loss of function mutation in WISP3 derived from
microsatellite unstable gastric carcinoma. Gastroenterology.
125:1563–1564. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Babic AM, Kireeva ML, Kolesnikova TV and
Lau LF: CYR61, a product of a growth factor-inducible immediate
early gene, promotes angiogenesis and tumor growth. Proc Natl Acad
Sci USA. 95:6355–6360. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin MT, Zuon CY, Chang CC, Chen ST, Chen
CP, Lin BR, Wang MY, Jeng YM, Chang KJ, Lee PH, et al: Cyr61
induces gastric cancer cell motility/invasion via activation of the
integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway.
Clin Cancer Res. 11:5809–5820. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin MT, Kuo IH, Chang CC, Chu CY, Chen HY,
Lin BR, Sureshbabu M, Shih HJ and Kuo ML: Involvement of
hypoxia-inducing factor-1alpha-dependent plasminogen activator
inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell
invasion. J Biol Chem. 283:15807–15815. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang WG, Hiscox S, Hallett MB, Horrobin
DF, Mansel RE and Puntis MC: Regulation of the expression of
E-cadherin on human cancer cells by gamma-linolenic acid (GLA).
Cancer Res. 55:5043–5048. 1995.PubMed/NCBI
|
|
33
|
Zuo GW, Kohls CD, He BC, Chen L, Zhang W,
Shi Q, Zhang BQ, Kang Q, Luo J, Luo X, et al: The CCN proteins:
Important signaling mediators in stem cell differentiation and
tumorigenesis. Histol Histopathol. 25:795–806. 2010.PubMed/NCBI
|
|
34
|
Watari H, Xiong Y, Hassan MK and Sakuragi
N: Cyr61, a member of ccn (connective tissue growth
factor/cysteine-rich 61/nephroblastoma overexpressed) family,
predicts survival of patients with endometrial cancer of
endometrioid subtype. Gynecol Oncol. 112:229–234. 2009. View Article : Google Scholar
|
|
35
|
Monnier Y, Farmer P, Bieler G, Imaizumi N,
Sengstag T, Alghisi GC, Stehle JC, Ciarloni L, Andrejevic-Blant S,
Moeckli R, et al: CYR61 and alphaVbeta5 integrin cooperate to
promote invasion and metastasis of tumors growing in preirradiated
stroma. Cancer Res. 68:7323–7331. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wei J, Yu G, Shao G, Sun A, Chen M, Yang W
and Lin Q: CYR61 (CCN1) is a metastatic biomarker of gastric cardia
adenocarcinoma. Oncotarget. Apr 20–2016.Epub ahead of print.
View Article : Google Scholar
|
|
37
|
Liu L, Li Z, Feng G, You W and Li J:
Expression of connective tissue growth factor is in agreement with
the expression of VEGF, VEGF-C, -D and associated with shorter
survival in gastric cancer. Pathol Int. 57:712–718. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu LY, Han YC, Wu SH and Lv ZH:
Expression of connective tissue growth factor in tumor tissues is
an independent predictor of poor prognosis in patients with gastric
cancer. World J Gastroenterol. 14:2110–2114. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jiang CG, Lv L, Liu FR, Wang ZN, Liu FN,
Li YS, Wang CY, Zhang HY, Sun Z and Xu HM: Downregulation of
connective tissue growth factor inhibits the growth and invasion of
gastric cancer cells and attenuates peritoneal dissemination. Mol
Cancer. 10:1222011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Inoki I, Shiomi T, Hashimoto G, Enomoto H,
Nakamura H, Makino K, Ikeda E, Takata S, Kobayashi K and Okada Y:
Connective tissue growth factor binds vascular endothelial growth
factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J.
16:219–221. 2002.
|
|
41
|
Sin WC, Bechberger JF, Rushlow WJ and Naus
CC: Dose-dependent differential upregulation of CCN1/Cyr61 and
CCN3/NOV by the gap junction protein Connexin43 in glioma cells. J
Cell Biochem. 103:1772–1782. 2008. View Article : Google Scholar
|
|
42
|
Fukunaga-Kalabis M, Martinez G, Telson SM,
Liu ZJ, Balint K, Juhasz I, Elder DE, Perbal B and Herlyn M:
Downregulation of CCN3 expression as a potential mechanism for
melanoma progression. Oncogene. 27:2552–2560. 2008. View Article : Google Scholar
|
